Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55390-0217-01 55390-0217 Idarubicin Hydrochloride Idarubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 15, 2007 Sept. 30, 2011 No Longer Used
00703-4154-11 00703-4154 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 1, 2002 Aug. 31, 2013 In Use
00703-4154-91 00703-4154 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 1, 2002 Dec. 31, 2012 In Use
00013-2586-91 00013-2586 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
00013-2586-10 00013-2586 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 11, 2024 In Use
00013-2596-91 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
00013-2596-20 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 11, 2024 In Use
57962-0014-28 57962-0014 Ibrutinib IMBRUVICA 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec. 20, 2017 In Use
57962-0140-09 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0140-12 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0280-28 57962-0280 Ibrutinib IMBRUVICA 280.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-28 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-71 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 6, 2019 In Use
57962-0007-12 57962-0007 Ibrutinib Imbruvica 70.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Aug. 24, 2022 In Use
57962-0560-28 57962-0560 Ibrutinib IMBRUVICA 560.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 Feb. 28, 2025 In Use
57962-0560-71 57962-0560 Ibrutinib IMBRUVICA 560.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 6, 2019 Dec. 31, 2020 In Use
68152-0104-04 68152-0104 Ibritumomab Tiuxetan Zevalin Immunotherapy Radioimmunotherapy CD20 Feb. 19, 2002 Dec. 3, 2011 No Longer Used
68152-0103-03 68152-0103 Ibritumomab Tiuxetan Zevalin Immunotherapy Radioimmunotherapy CD20 Feb. 19, 2002 Oct. 26, 2020 In Use
00310-4715-11 00310-4715 IV Solution Stabilizer for Lumoxiti IV Solution Stabilizer for Lumoxiti 6.5 mg/mL Ancillary Therapy Excipient Intravenous Oct. 24, 2018 In Use
72143-0252-30 72143-0252 ISOTRETINOIN ACCUTANE 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
72143-0253-30 72143-0253 ISOTRETINOIN ACCUTANE 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
72143-0254-30 72143-0254 ISOTRETINOIN ACCUTANE 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
72143-0251-30 72143-0251 ISOTRETINOIN ACCUTANE 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 1, 2022 In Use
59651-0631-03 59651-0631 ISOTRETINOIN ISOTRETINOIN 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use

Found 10,000 results in 13 milliseconds — Export these results